Lucid's new CEO launched a sweeping turnaround plan and called out years of failure in unusually blunt terms, yet the stock hit a 52-week low days later. Something in that reset spooked…
The capital you need to retire on dividends alone swings by millions depending on one number, and chasing the wrong yield can quietly erode everything you built.
Bank of America dropped a fresh price target on Affirm just as yields began to ease, and the combination sent buy-now-pay-later stocks racing ahead of a sleepy broad market. Whether the rally…
FuboTV is surging midday with no earnings release, no filing, and no corporate announcement to explain it. Something is shifting in how the market values the combined live TV bundle, and it…
Baird just reframed the biggest risk hanging over Reddit stock, and the market responded with its sharpest single-day move in months. Here is what two expiring AI licensing deals actually mean for…
J.P. Morgan just praised Nio's quarter and punished the stock at the same time, and the reason behind that split verdict is reshaping how investors see the entire China EV sector.
SPYI's monthly distribution looks like income, but part of that check may be quietly returning your own principal while reshaping the tax bill waiting at the end of the line.
Coca-Cola has quietly outrun every beverage rival and beaten the broader market in 2026, but the three-digit milestone that investors are fixating on sits just beyond where Wall Street's own analysts are…
Target has sprinted past Walmart, Costco, and the broader market this year, but analyst consensus sits below the current share price and the majority verdict is hold. Find out what earnings milestone…
Morgan Stanley has lapped every major bank rival in 2026, but a rate spike just rattled the stock and the one price level that would confirm the bull case remains stubbornly out…
Nio just posted its most profitable quarter in years, yet investors are dumping the stock. The culprit is a cost pressure that has nothing to do with cars and everything to do…
GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where the real…
PJM yanked a Meta-backed nuclear campus from its grid queue, hitting Oklo with a company-specific blow on top of a sector already reeling from surging Treasury yields. How those two pressures compound…
Retail traders are piling into Novavax on cancer-vaccine speculation, but the move that actually changed the company's business model happened quietly last week and has nothing to do with oncology.
A global bond selloff is carving a precise line through fintech, punishing two lenders while leaving one brokerage almost untouched, and the reason why reveals exactly how rate exposure separates winners from…
